Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells

Aruna Raja 1,†, Soha Ahmadi 1,2,†, Fernanda de Costa 3, Nan Li 3 and Kagan Kerman 1,*

1 Department of Physical and Environmental Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada; aruna.raja@utoronto.ca (A.R.); soha.ahmadi@mail.utoronto.ca (S.A.)
2 Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada
3 Lupos Biotechnology Inc., 221 Morrish Road, Toronto, ON M1C 1E9, Canada; fernanda.decosta@lupos.ca (F.d.C.); nan.li@lupos.ca (N.L.)
* Correspondence: kagan.kerman@utoronto.ca
† These authors contributed equally to this work.

Received: 22 August 2020; Accepted: 10 October 2020; Published: 22 October 2020

Abstract: In this proof-of-concept study, the antioxidant activity of phytocannabinoids, namely cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC), were investigated using an in vitro system of differentiated human neuronal SY-SH5Y cells. The oxidative stress was induced by hydrogen peroxide, as reactive oxygen species (ROS). Alzheimer’s disease (AD)-like pathological conditions were mimicked in vitro by treating the differentiated neuronal cells with amyloid-β1–42 (Aβ1–42) in the presence of Cu(II). We showed that THC had a high potency to combat oxidative stress in both in vitro models, while CBD did not show a remarkable antioxidant activity. The cannabis extracts also exhibited a significant antioxidant activity, which depended on the ratio of the THC and CBD. However, our results did not suggest any antagonist effect of the CBD on the antioxidant activity of THC. The effect of cannabis extracts on the cell viability of differentiated human neuronal SY-SH5Y cells was also investigated, which emphasized the differences between the bioactivity of cannabis extracts due to their composition. Our preliminary results demonstrated that cannabis extracts and phytocannabinoids have a promising potential as antioxidants, which can be further investigated to develop novel pharmaceuticals targeting oxidative stress therapy.

Keywords: antioxidant; SY-SH5Y cells; cannabinoid; THC; CBD; reactive oxygen species; oxidative stress; amyloid-β

1. Introduction

One of the oldest known medicinal plants to mankind, Cannabis sativa L. (C. sativa L.), has been used for various applications spanning over thousands of years [1]. C. sativa L. is an annual, dioecious flowering plant. Its first occurrence is believed to be in central Asia [2]. Although the written records of cannabis use both medicinally and recreationally have been found dating back to the 13th Century, extensive interest started in the 19th Century for the preparation of various aliments with anticonvulsive, analgesic, anxiolytic and antiemetic properties [3]. Cannabis contains more than 500 natural compounds including oils, proteins, metabolites and fibers [4], of which, more than 200 are metabolites including terpenoids, flavonoids, alkaloids and phytocannabinoids [5]. Phytocannabinoids, a chemical class of C21 terpenophenolic compounds produced uniquely by cannabis, are the most bioactive metabolites of cannabis. They have a lipid structure featuring alkylresorcinol, which is classified as neutral cannabinoids (without carboxyl group) and cannabinoid acids (with carboxyl group). Cannabinoids are accumulated as cannabinoid acids and decarboxylated into their neutral forms. Trans-∆9-tetrahydrocannabinol (THC;
Figure 1) is one of the most potent cannabinoids responsible for the psychoactive effects [6], whereas cannabidiol (CBD, Figure 1) is non-psychoactive [7]. Apart from these, other known phytocannabinoids are cannabiol (CBN), cannabichromene (CBC) and cannabigerol (CBG) (Figure 1), among others [8,9]. Cannabinoids activate a group of receptors in the body called cannabinoid receptors, CB1 and CB2, which are responsible for various physiological processes, including memory, appetite, mood and pain perception. Prandi et al. [10] provided a comprehensive review of the structure-activity relationship (SAR) mechanisms between cannabinoids and their receptors.

THC is a partial agonist to cannabinoid receptors CB1 and CB2 [11,12]. The CB1 receptor is mainly found in the central nervous system, while CB2 is predominant in the immune system [13]. THC is readily absorbed and also passes through the blood-brain barrier due to its lipophilic nature [11]. On the other hand, CBD exerts an anti-inflammatory effect by inhibiting NF-kB and interferon-β along with analgesic actions in cancer [14]. CBD has a low binding affinity towards CB1 with the capacity to antagonize CB1 at nM levels [12]. THC and its analogs have been shown to reduce glutamate toxicity by activating the cannabinoid receptors and reducing the influx of calcium through voltage-sensitive calcium channels [15,16]. We have recently reported on the radical scavenging activity of THC and CBD in the absence of SH-SY5Y cells using UV-Vis assays based on the colorimetric reactions between reactive oxygen species (ROS) and 2,2-diphenyl-1-picryl-hydrazyl-hydrate (DPPH), 2,2-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and hypochlorous acid (HOCl) [17]. We also applied electrochemical techniques to evaluate the antioxidant activity of THC and CBD using voltammetry [17].

Oxidative stress refers to an imbalance between the production of ROS and the antioxidant defense mechanism causing timely clearance from the biological system [18]. Oxidative stress processes create a significant amount of free radicals. These free radicals are unstable due to the presence of unpaired electrons, which can react freely with biomolecules (lipids, protein, nucleic acid and carbohydrates), causing susceptibility to irreversible damage [19].

Studies performed in vitro have shown that CBD has anti-inflammatory and antioxidant properties [20], as well as reducing tau phosphorylation related to Alzheimer’s disease (AD) [21] and improving cell viability [22]. The ratio of administered CBD to THC significantly influenced these possible effects [23,24]. Different ratios of THC and CBD were utilized in assays such as the estimation the GABA (gamma-aminobutyric acid, a neurotransmitter) levels, Nissl-stained neurons and the mRNA level of antioxidant enzymes such as superoxide dismutase (SOD-1) to judge the neuroprotective effects.
on the neurons [23,24]. The changes introduced in the expression levels of SOD-1 by 3-nitropropionic acid (3-NP) were completely reversed by using THC and CBD [23,24]. The commercially available form of THC, Dronabinol™, has been used successfully to increase appetite in the case of AIDS and as an antiemetic in the case of cancer chemotherapy [25]. Baker and Pryce [26] recently reviewed the antioxidative and anti-inflammatory properties of CBD. THC has shown neuroprotective effects in animal models of AD, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) through modulation in glutamatergic transmissions and synaptic plasticity, as well as the modulation of immune response and the excitability of N-methyl-D-aspartate receptors [27].

The key role of cannabinoid receptors in AD makes cannabinoids and cannabis extracts a potential therapeutic candidate for AD [28–30]. AD is a progressive degenerative disease of the brain. It is characterized by memory decline, disruption of cognitive ability and eventual loss of bodily function control [31]. Our current understanding of the pathological mechanism of the disease includes aspects such as the involvement of amyloid-beta (Aβ) plaques and the formation of neurofibrillary tangles, along with oxidative stress and inflammatory events, eventually leading to neuronal injury and synaptic loss [32]. For more than two decades, the Aβ hypothesis has been the primary pathophysiology behind AD [33]. According to the amyloid hypothesis, an imbalance between the generation and clearance of Aβ from the brain is the major contributor to the progression of AD pathogenesis [34]. Aβ leads to neuronal lipid peroxidation, protein oxidation and DNA oxidation [35]. Lyras et al. [36] tested different regions of the human brain to assess the level of protein and DNA oxidation. Their results were conclusive concerning the role of oxidative stress in key regions of the human brain implicated in AD. Among other leading causes of AD, metal ion imbalance plays a major role. At the synaptic clefts of AD brains, Aβ1–42, Cu(II) (400 mM) and Fe(III) (1 mM) were detected at anomalous levels, causing Aβ aggregation and ROS production [37,38]. Protease resistance, reversible precipitation and the O2−-dependent production of H2O2 and concomitant toxicity are all mediated by the affinity of Cu(II) and Zn(II) towards Aβ [39]. Studies have shown that Aβ peptides cause cellular toxicity by generating H2O2 and O2− radicals in vitro [40,41]. Post-mortem AD brain tissue has shown plaques enriched with Aβ1–42 in combination with Cu/Zn, and these Aβ-metal complexes were solubilized with the selected metal chelators [42,43]. Furthermore, the interaction of Cu(II) with tau protein also lead to ROS formation and neuronal death [44,45].

Since AD is a multifactorial disease, the therapeutic approach should be targeted at various levels. Most of the experimental evidence as discussed above is available from both cellular and animal models with regard to the potential of cannabinoids. One of the clinical results has shown that treatment with THC analogs resulted in decreased severity in the cognitive behavior of AD patients [46] and increased their appetite [47]. Another cellular studies showed that cannabinoids lowered the Aβ levels, inhibited their aggregation and increased mitochondrial function [48,49].

In this study, we investigated the effect of the cannabis extracts, as well as THC and CBD, two main bioactive phytocannabinoids, to combat oxidative stress, one of the hallmarks of AD, using an in vitro model of the neurons. We evaluated the effect of cannabis extracts on the cell viability of the differentiated SH-SY5Y neuronal cell line using fluorescence-based techniques. Our aim in this study was to lay a background for future research with regard to the potential applications of cannabinoids and their synthetic analogs as a novel therapeutic approach to oxidative stress in AD.

2. Results and Discussion

2.1. Antioxidant Activity

To investigate the antioxidant activity of the phytocannabinoids and cannabis extracts, we developed an in vitro model of AD-like oxidative stress using the differentiated SH-SY5Y cells. We followed two approaches to mimic the AD-like oxidative stress by treating the differentiated SH-SY5Y cells with H2O2 and also with Aβ1–42 and Cu(II) to provide an in vitro model of AD-like oxidative stress.
The in vitro model of AD-like oxidative stress was developed by treating the differentiated SH-SY5Y neuronal cells with two known oxidative stress inducers, namely hydrogen peroxide (H$_2$O$_2$) [50–52] and A$\beta_{1–42}$ in the presence of Cu(II) (A$\beta_{1–42}$-Cu(II) complex) [53,54]. To determine the level of ROS produced by the inducers, DCFDA, a cell-permeable reagent, was used. This reagent was deacetylated by the cellular esterase to an intermediate compound, which was later oxidized by reactive oxygen species (ROS) to 2′,7′-dichlorofluorescein (DCF). This highly fluorescent compound (DCF) was then measured spectrophotometrically at an excitation of 495 nm and an emission of 529 nm.

The effect of H$_2$O$_2$ is largely mediated by hydroxyl radicals (OH$^*$) generated by the Fenton reaction, which is catalyzed by Fe$^{2+}$ [55]. Previous studies have shown that Cu(II) also has an important role in the Fenton reaction to generate ROS [44,45,56]. Postmitotic brain cells such as glial and neuronal cells are particularly sensitive to these free radicals, leading to brain damage [57]. Differentiated SH-SY5Y cells provided us with an ideal model to test the effectiveness of cannabinoids against the oxidative stress environment in pathological conditions. Our previously reported UV-Vis studies showed that THC and CBD had a similar potency using the DPPH, ABTS and HOCl radical scavenging assays [17]. However, the result of this study indicated that THC (IC$_{50}$ = 0.4 µg mL$^{-1}$) had a higher potency in combating the ROS induced by H$_2$O$_2$ in the SY-SH5Y cells compared to CBD with an IC$_{50}$ of 42.7 µg mL$^{-1}$ (Table 1).

Table 1. ROS detection assay in differentiated SH-SY5Y cells using H$_2$O$_2$ as the oxidative stress inducer.

| Test Compound | CBD% | THC% | IC$_{50}$ (µg mL$^{-1}$) * |
|---------------|------|------|---------------------------|
| Ascorbic Acid | —    | —    | 0.25                      |
| THC           | —    | 98   | 0.4$_4$                   |
| 10:90         | 10   | 90   | 2.5$_4$                   |
| 25:75         | 25   | 75   | 0.4$_4$                   |
| 50:50         | 50   | 59   | 0.5$_4$                   |
| 75:25         | 75   | 25   | 1$_4$                     |
| 90:10         | 90   | 10   | 5$_4$                     |
| CBD           | 98   | —    | 42.7$_1$                  |
| E3            | N.D.$^#$ | 71.08 | 0.4$_4$                   |
| E8            | 50.34 | 3.9  | 0.5$_4$                   |
| E2            | N.D.$^#$ | 81.1 | 0.7                      |
| E7            | 64.34 | 11.54 | 0.6$_4$                   |
| E1            | N.D.$^#$ | 72.88 | 1.2$_4$                   |

* Results are expressed as the mean of triplicates. Average values followed by different numbers (subscript numbers:1–4) differ by the Bonferroni test at $p < 0.05$. $^#$ Not detected.

The cannabis extracts were also tested using the DCFDA assay to detect their ability to decrease ROS levels after H$_2$O$_2$ treatment for 24 h (Figure 2A). Table 1 shows the IC$_{50}$ of all the tested extracts and cannabinoid compounds. Ascorbic acid (AA) was applied as a positive control with a known strong antioxidant effect [58,59]. Among all the cannabis extracts, E3 with 71.08% THC and no detectable CBD showed the highest antioxidant activity by reducing the ROS level by 80% (Figure 2A). The other cannabis extracts (E1) that also contained a close amount of THC (72.88%) and no detectable CBD reduced the ROS by more than 70%. Notably, these two extracts also showed similar neurotoxicity (Table 2). Interestingly, extracts E7 and E8, which were poor in THC (11.5% and 3.9%, respectively), were also effective at reducing the ROS by more than 60%. We also examined the effectiveness of the CBD:THC compounds at different proportions (Figure 2B). As expected, the sample mixture with the lowest amount of THC (90:10 of CBD:THC) was less effective at decreasing the ROS level. Our results showed that pure THC (98% pure) reduced the ROS at the same level of AA with an IC$_{50}$ of 0.4 µg mL$^{-1}$,
while pure CBD only reduced the ROS by 50% with an IC\textsubscript{50} of 42.7 µg mL\textsuperscript{-1} (Table 1). These results suggest that other metabolites in the cannabis extracts might be associated with antioxidant activity.

![Figure 2](image-url)

**Figure 2.** Concentration-response curve for monitoring the ROS level in differentiated SH-SY5Y cells using the 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) assay after treatment (A) with cannabis extracts (tested concentrations for the extracts: 0.0, 0.8, 2.5, 7.4, 22.2, 66.7 and 200.0 µg mL\textsuperscript{-1}) and (B) the inset; and CBD:THC (C) solutions with different ratios of CBD and THC (tested concentrations for the CBD:THC ratios: 0.0, 0.4, 1.2, 3.7, 11.0, 33.0 and 100.0 µg mL\textsuperscript{-1}) and along with (D) the inset. In all experiments, H\textsubscript{2}O\textsubscript{2} was used as the ROS inducer (100% fluorescence intensity), and ascorbic acid (AA) was tested in vehicle only (DMSO) as the positive control. Data show the average of the mean values determined in triplicate measurements (\(n = 3\)). Control (from vehicle only, DMSO) vs. response data (from cannabinoids) are shown using the Bonferroni test at \(p < 0.0001\).

Other constituents of the tested extracts, i.e., CBN, CBG, etc. could either enhance the effects of THC or be reduced by CBD in their antioxidant properties [7]. Studies have shown that in the mixed proportion of CBD and THC, sometimes, CBD hindered the effect of THC, and in other cases, it could potentiate its effect, making it difficult to establish a fixed ratio with the desired potency [24]. Our results also showed that the ratio of CBD:THC at 25:75 showed a high potency with an IC\textsubscript{50} of 2.5 µg mL\textsuperscript{-1} and was found to be more potent than a CBD:THC ratio of 10:90 with an IC\textsubscript{50} of 5 µg mL\textsuperscript{-1}. 
Table 2. IC$_{50}$ of THC, CBD, cannabiol (CBN) and cannabis extracts (E) against differentiated SH-SY5Y cells as determined by the MTT assays.

| Test Compounds | CBD% | THC% | IC$_{50}$ ($\mu$g mL$^{-1}$) * |
|---------------|------|------|-------------------------------|
| THC           | —    | 98   | 0.6                           |
| E3 N.D.       | 71.80| 0.6  |
| E1 N.D.       | 72.88| 0.7  |
| CBD           | 98   | —    | 5                             |
| CBN           | —    | —    | 6.5                           |
| E2            | —    | 81.10| 7                             |
| E7            | 64.34| 11.54| 11                            |
| E8            | 50.34| 3.90 | 11                            |

* Results are expressed as the mean of triplicates. Average values followed by different numbers (1–4) differ by the Bonferroni test at $p < 0.05$. # Not detected.

It has been shown by several researchers that the interaction of Cu(II) with peptides and proteins leads to ROS formation [44,45,56,60,61]. Therefore, the A$\beta$-Cu(II) system can be used as an oxidative stress inducer in the SH-SY5Y in vitro model to mimic the AD-like oxidative stress condition [62,63]. Among the A$\beta$ isoforms, A$\beta$_1-42 is more hydrophobic and fibrillogenic than A$\beta$_1-40 due to the addition of two hydrophobic residues at the N-terminus [64]. A$\beta$_1-42 in combination with Cu(II) catalyzes reactive oxygen species production [65]. The high binding affinity of Cu(II) to three histidine residues at positions 6, 13 and 14 facilitates the aggregation of A$\beta$_1-42 [66]. The neurotoxicity of A$\beta$_1-42 is significantly increased in the presence of Cu(II) compared to A$\beta$_1-40, correlating with the capacity to reduce Cu(II) to Cu(I), while forming H$_2$O$_2$ and oxidative stress [67]. In order to find the concentration level of the A$\beta$_1-42-Cu(II) system that produces the highest neurotoxicity, the differentiated SH-SY5Y cells were treated with different concentrations of A$\beta$_1-42, Cu(II) and A$\beta$_1-42-Cu(II) (molar ratio 1:1). The cell viability of differentiated SH-SY5Y cells after 24 h of treatment was examined by the MTT assay (Figure 3). Figure S1 displays the phase-contrast images. The MTT results confirmed the neurotoxicity of A$\beta$_1-42 and A$\beta$_1-42-Cu(II) (molar ratio 1:1). As expected, treatment with A$\beta$_1-42-Cu(II) reduced the cell viability more than A$\beta$_1-42 (with the same concentration). This observation emphasized the possible role of A$\beta$_1-42-Cu(II) in ROS formation, and this was in agreement with previous studies [67,68]. The 10 $\mu$M A$\beta$_1-42-Cu(II) (molar ratio 1:1) cell viability was decreased by more than 50% after 24 h of treatment. Therefore, this concentration was chosen as the ROS inducer in the SH-SY5Y in vitro model. A cannabis extract (E2) (see Table S1 for the details of the composition), which contained 81.08% THC, with no detectable CBD, and hemp seed oil (HSO) containing 80% CBD was chosen as the natural source of THC and CBD, which allowed us to compare the effectiveness of THC and CBD to study the oxidative stress induced by the A$\beta$_1-42-Cu(II) system. Irakli et al. [69] recently investigated the nutritional, phytochemical composition and antioxidant properties of hemp seeds. The differentiated neuronal cells were treated with various concentrations of E2 and HSO after pre-treating the SH-SY5Y cells with a 10 $\mu$M A$\beta$_1-42-Cu(II) complex (molar ratio 1:1).
When HIV-infected T lymphocytes produce high amounts of interferon-α, they can activate neuronal viability. We also performed a series of MTT assays to further investigate the effectiveness of THC and CBD to study the oxidative stress induced by Aβ1–42 and Aβ1–40, correlating with the toxicity towards Cu(II) and reduced the formation of H₂O₂ by Aβ1–42 [43]. Though the mechanism of action for cannabinoids in reducing the oxidative stress created by Aβ1–40 is not yet known, we hypothesize that the metal chelating properties of THC and CBD could be the probable explanation. Further investigations on this hypothesis are in progress in our laboratory. Figure S4 shows the concentration-response curve of E2 for ROS level detection in the differentiated SH-SY5Y neuronal cells when H₂O₂ was used as the ROS inducer. These results reinforced the previous study that reported the effect of THC to inhibit Aβ1–42 aggregation [11]. We can speculate that THC had a dual action on the Aβ1–42-Cu(II) system by reducing ROS formation and inhibiting Aβ1–42 aggregation, which might have prevented neuronal death. However, comparing the antioxidant activity of the phytocannabinoids and cannabis extracts in two AD-like oxidation models suggested a complex antioxidant mechanism that may follow various pathways. Therefore, further studies need to be done to understand the mechanism of the antioxidation and the possible role of cannabinoid receptors that are activated by these compounds. We also performed a series of MTT assays to further investigate the effect of cannabinoids on neuronal viability.

Figure 3. Bar chart illustrating the cell viability, using the MTT assay, of the differentiated SH-SY5Y neuronal cells after 24 h of incubation with amyloid-β (Aβ) (green bar), Cu(II) (red bar), the Aβ + Cu(II) complex (molar ratio 1:1) (blue bar) and control experiments with no treatment of oxidative stress inducers (yellow bar).
performed. Figure 5 shows the dose-response curve for CBD, THC and CBN against differentiation of SH-SY5Y. The concentration ranges were from 0.0001 µg mL\(^{-1}\) to 200.00 µg mL\(^{-1}\). The IC\(_{50}\) values for these cannabis extracts (Table 2) were determined based on the dose-response curve. In order to examine the impact of CBD, THC and CBN on the neurotoxicity of these extracts, MTT assays were performed. Figure 5 shows the dose-response curve for CBD, THC and CBN against differentiated SH-SY5Y. The dose-response curve for different cannabis extracts is shown in Figure S2. The IC\(_{50}\) of these cannabis extracts and cannabinoids (THC, CBD and CBN) was calculated based on the dose-response curve (Table 2). The concentration ranges were from 0.0001 µg mL\(^{-1}\) to 13 µg mL\(^{-1}\) for THC, from 0.01 µg mL\(^{-1}\) to 74 g/mL\(^{-1}\) for CBD and from 0.001 µg mL\(^{-1}\) to 100 µg mL\(^{-1}\) for CBN. While CBD (<1 µg mL\(^{-1}\)) and CBN (<5 µg mL\(^{-1}\)) did not show any neurotoxicity, THC treatment reduced the cell viability of differentiated SH-SY5Y by 50% at a 0.6 µg mL\(^{-1}\) concentration (Figure 5).
Cannabis extracts E1 and E3 with high THC (>71%) showed a similar effect to pure THC (Table 2). Furthermore, these extracts had a lower IC\textsubscript{50} in comparison with extracts E7 and E8, which had more than 50% CBD and a low THC proportion. Notably, extracts E7 and E8 (IC\textsubscript{50} = 11 µg mL\textsuperscript{-1}) were less neurotoxic than the pure CBD (IC\textsubscript{50} = 5 µg mL\textsuperscript{-1}). On the other hand, cannabinol (CBN), having a structure like THC (Figure 1), was found to have an IC\textsubscript{50} of 6.5 µg mL\textsuperscript{-1}, which was 10-fold higher than THC. The extracts tested not only had different ratios of THC and CBD, but also other naturally occurring compounds like cannabigerol (CBG) and cannabichromene (CBC) (see Table S1 for the metabolite profile of these cannabis extracts). These other constituents of the extracts tested have their own therapeutic potential, which could either have a synergistic or antagonistic effect in the cells. We are currently in the process of investigating those individual and combined effects of...
CBG and CBC in our laboratory. Previous studies showed that CBG was non-psychoactive and did not bind to the CB1 or CB2 receptors, but displayed antioxidant and anti-inflammatory properties [60]. Prior literature indicated that these constituents might synergistically enhance the effect of the primary phytocannabinoids and mitigate their side effects, especially with regards to THC [5]. Recently, di Giacomo et al. [70] reported the neuroprotective and neuromodulatory effects induced by CBD and CBG in rat Hypo-E22 cells and isolated hypothalamus. This information would be useful to find an optimal concentration to attain the beneficial effects of phytocannabinoids in cannabis extracts towards neurodegenerative disease treatment.

To test which proportion (devoid of other cannabinoid constituents) was responsible for these effects, different ratios of pure THC and CBD were investigated as control assays (Figure S3 and Table S2). The ratios tested for cell viability were 90:10, 75:25, 50:50, 25:75 and 10:90 (w/w of CBD:THC). While all the tested THC:CBD solutions were nontoxic below a 1 µg mL−1 concentration, the 50:50 ratio of THC:CBD had the highest IC50 among all the tested solutions.

The effect of cannabinoids on the morphology of the differentiated neuronal cells was also investigated by phase-contrast microscopy. Figure 6 shows the phase-contrast microscopy images of the differentiated neuronal cells after treatment with CBD. The negative control used for this test was DMSO (Figure 6A), having slender shaped cells with elongated neurites. The neuronal cells displayed negligible bulging but had intact neurites at a concentration of 0.1 µg mL−1 of CBD (Figure 6B). Images indicated that cells started to round, and that neurite formation was affected around 2 µg mL−1 (Figure 6C), and a concentration of 10 µg mL−1 of CBD (Figure 6D) and above caused cell death. Figure S5 shows the phase-contrast images of the differentiated SH-SY5Y cells after treatment with various concentrations of THC.

![Figure 6](image_url)

**Figure 6.** Phase-contrast microscope images of differentiated SH-SY5Y after treatment with (A) DMSO as the control, (B) 0.1 µg mL−1 CBD, (C) 2 µg mL−1 CBD and (D) 10 µg mL−1 CBD. CBD at a concentration of 10 µg mL−1 (D) and above shows dead cells, at 2 µg mL−1 (C) causes cell body rounding and less affected neurites, whereas at 0.1 µg mL−1 (B), the phenotype is almost similar to the DMSO ((A), vehicle only control) phenotype. Images were taken using the EVOS M5000 Imaging System at 10× magnification. The scalebar indicates 50 µm.
3. Materials and Methods

3.1. Materials

Dulbecco’s Modified Eagle’s Medium (DMEM) was obtained from Wisent Bioproducts (Montreal, QC, Canada). Fetal bovine serum (FBS) and 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA) were purchased from Thermo Scientific (Waltham, MA). ∆9-THC (1 mg mL⁻¹ in methanol) was acquired from Cayman Chemical Company (Ann Arbor, MI, USA). CBD was provided by Lupos Biotechnology Inc. (Toronto, ON, Canada). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent, all-trans-retinoic acid, hydrogen peroxide (H₂O₂), Cu(II) chloride, dimethyl sulfoxide (DMSO, 99.9%), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, 99.0%) and ascorbic acid (AA) were purchased from Sigma-Aldrich (Oakville, ON, Canada). All the chemicals used were of analytical grade and used as received.

3.2. Amyloid-β Pretreatment

The Aβ₁₋₄₂ peptide was purchased from Anaspec (Fermont, CA, Canada). Briefly, Aβ₁₋₄₂ peptides were pre-treated by dissolving in HFIP to a final concentration of 1 mg mL⁻¹. The resulting suspensions were sonicated for 15 min until the sample solutions became clear. Aβ₁₋₄₂/HFIP solutions were shaken at 400 rpm for 2 h at 4 ± 1 °C. The samples were then left in HFIP and sealed overnight. HFIP was then removed by passing a stream of nitrogen gas across the solvent surface, leaving a clear thin film of peptides at the bottom of the sample vial. The thin film of peptides was re-constituted in DMSO and mixed by vortexing, followed by dilution to the appropriate concentrations with 50 mM PBS containing 100 mM NaCl (pH 7.4). Peptide concentrations were determined by measuring the OD at 280 nm (ε₂₈₀ = 1280 M⁻¹) using a NanoDrop 2000 (ThermoScientific, Mississauga, ON, Canada).

3.3. Cannabis sativa L. Extracts

Cannabis extracts E1, E2, E3, E7 and E8, which were extracted from Cannabis sativa L. by the supercritical carbon dioxide extraction technique, were kindly provided by Lupos Biotechnology Inc. (Toronto, ON, Canada) and were used as received. All the extracts were analyzed by GC-MS at Lupos Biotechnology Inc. (Toronto, ON, Canada) (Table S1). Stock solutions of cannabis extracts were prepared in the DMSO and diluted to the desired concentrations before the treatment. CBD and THC standards as isolated compounds and combined at different ratios CBD:THC (90:10, 75:25, 50:50, 25:75 and 10:90 (w/w)) were also studied for their antioxidant activity.

3.4. Cell Culture and Neuronal Differentiation

The human SHSY5Y neuronal cell line (American Type Culture Collection, Manassas, VA, USA) was maintained in DMEM supplemented with 10% FBS. Cultures were incubated at 37 °C in a humidified 5% CO₂ atmosphere. The SHSY5Y cells were differentiated by all-trans-retinoic acid (RA) using a well-established protocol as reported before [71]. Briefly, after plating the cells at a cell density of 3.5 × 10⁴ cells per cm² to allow cell adhesion for 24 h, neuronal differentiation was induced by treatment of the cells with 10 µM RA at 37 °C for 72 h under serum-free DMEM conditions.

3.5. Cell Viability Assay

The cell viability of the differentiated SH-SY5Y cells was monitored after treatment with various concentrations of cannabis extracts or phytocannabinoids. The differentiated SH-SY5Y cells were also treated with various concentrations of Cu(II) and Aβ₁₋₄₂ in the absence or presence of Cu(II) to find the neurotoxicity that mimics the AD-like oxidative stress condition [53,54]. In all experiments, DMSO was used as the vehicle control. The MTT assay was performed to determine the cell viability after 24 h of treatment with the target extracts or compounds. The MTT assay is a colorimetric technique that uses the reduction of a yellow MTT reagent to measure cell viability. Viable cells
contained NAD(P)H-dependent oxidoreductase enzymes, which reduced the MTT reagent to formazan, an insoluble crystalline product with a deep purple color. The standard procedure was followed for the MTT assay: Briefly, 0.2 mg mL$^{-1}$ MTT solution in DMEM were added to each well of a 96 well plate, and the plate was incubated for 4 h at 37 °C in a humidified 5% CO$_2$ atmosphere. After 4 h, the media were aspirated, and one hundred microlitres of DMSO were added to each well. The absorbance of the wells was measured at 570 nm, which directly correlates to the number of viable cells, using a microplate reader (Synergy H1 multi-mode reader, BioTek Instruments Inc., Winooski, VT, USA). Cell viability was further confirmed by examination of the cellular morphology with phase-contrast microscopy (EVOS M5000 Imaging System, Thermo-Fisher Scientific, Mississauga, ON, Canada). Dying cells showed extensive rounding of the cell body and condensation of nuclei.

3.6. Antioxidant Activity Assay

SH-SY5Y cells at a density of 3.5 × 10$^4$ per well were seeded into a dark plate with a clear bottom. After 24 h of incubation at 37 °C, the cells were treated with 10 μM RA at 37 °C for 72 h under serum-free conditions to induce differentiation. The cells were then treated with 100 μM of H$_2$O$_2$ for 24 h to create oxidative stress in the cells, as reported before [50,51]. The differentiated cells were treated with 5 μM of DCFDA for 30 min to get a measure of the baseline oxidative stress of the cells before being treated with the test compounds. A range of concentrations was used to test the efficacy of the extracts and pure compounds in rescuing the cells after inducing oxidative stress by H$_2$O$_2$. The cells were incubated with the test compounds for 30 min before measuring the fluorescence at excitation/emission of 492 nm/527 nm using a microplate reader (Synergy H1 multi-mode reader, BioTek Instruments Inc., Winooski, VT, USA). AA was applied as a positive control. To investigate the effect of the Aβ$_{1-42}$-Cu(II) complex as the oxidative stress inducer, the differentiated SH-SY5Y cells were treated with 10 μM of the Aβ$_{1-42}$-Cu(II) complex with a molar ratio of 1:1. The DCF fluorescence intensity of the cells treated with H$_2$O$_2$ or Aβ$_{1-42}$-Cu(II) was considered as 100%, and the relative fluorescence intensity was calculated for all the samples accordingly.

3.7. Statistical Analysis

Data are presented as the mean ± SD. The Bonferroni test was used to evaluate statistical discrepancies between the two groups. $p < 0.05$ was used as the criterion for statistical significance.

4. Conclusions

In this proof-of-concept study, we investigated the effects of cannabis extracts with different ratios of THC and CBD on combating the oxidative stress in differentiated neuronal cells. To understand the role of phytocannabinoids, specifically CBD and THC, in the antioxidant activity of the cannabis extracts, we also examined the effect of pure THC, CBD, as well as various mixtures of these two phytocannabinoids. The oxidative stress was induced in vitro in differentiated neuronal SH-SY5Y cells using H$_2$O$_2$. Our results showed that the 75% THC compound and cannabis extract containing 72% THC could reduce ROS formation by approximately 80%. We also mimicked the AD-like oxidative stress conditions by treating the differentiated neuronal SH-SY5Y cells using Aβ$_{1-42}$-Cu(II) complexes, which also triggered ROS formation. Our results clearly showed the significant impact of cannabis extracts with high THC to combat ROS formation induced by the Aβ$_{1-42}$-Cu(II) in vitro model. However, CBD was not observed to exhibit as high an antioxidant activity as THC under these experimental conditions. The antioxidant activity of cannabis extracts that had a lower percentage of THC suggested that other natural compounds in these extracts might also have had antioxidant activity or a synergetic effect. Our results provide fundamental information on the antioxidant activity of cannabinoids on neuronal cells towards developing a novel therapeutic approach for oxidative stress therapy. Further studies are required to understand the role of cannabinoid receptors, as well as other receptors that may be activated by these compounds in SH-SY5Y cells. Research efforts towards...
understanding the molecular mechanisms underlaying the antioxidant activities of phytocannabinoids is in progress in our laboratory.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/1424-8247/13/11/328/s1, Figure S1: Phase-contrast microscope images of (A) the differentiated SH-SY5Y without treatment; (B) after treatment with 10 μM Aβ1-42; (C) 10 μM Cu(II); and (D) 10 μM Aβ-Cu2+ (molar ratio 1:1) complex for 24 h. Scale bars indicate 400 μm, Figure S2: Dose-response curve of MTT cell viability assay with different cannabis extracts (A) E1, (B) E3, (C) E7, (D) E8, (E) E2 in the differentiated SH-SY5Y cells, Figure S3: Dose-response curve of MTT cell viability assay in the differentiated SH-SY5Y cells with CBD:THC ratios (A) 90:10, (B) 75:25, (C) 50:50, (D) 25:75, and (E) 10:90, Figure S4: Concentration-response curve for monitoring the ROS level in differentiated SH-SY5Y cells using DCFDA assay after treatment (A) with cannabis extract E2 and (B) inset displaying the data from low concentrations of E2, Figure S5: Phase-contrast microscope images of differentiated SH-SY5Y after treatment with (A) DMSO as the control (vehicle only), (B) 0.1 μg mL⁻¹ THC, (C) 2 μg mL⁻¹ THC, and (D) 10 μg mL⁻¹ THC, Table S1: Chemical profile of cannabis extracts obtained from GC-MS analysis, Table S2: IC50 of CBD:THC solutions obtained from MTT cell viability assay.

**Author Contributions:** A.R.: investigation, methodology, formal analysis, data curation, writing, original draft. S.A.: investigation, methodology, formal analysis, data curation, writing, review and editing. F.d.C.: investigation, methodology, formal analysis. N.L.: conceptualization, project administration, funding acquisition. K.K.: conceptualization, project administration, funding acquisition, supervision, writing, review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was financially supported by the Ontario Center of Excellence (Voucher for Innovation and Productivity-1 (VIP-1) (Project #31094) and the Ontario Ministry of Economic Development and Innovation (Project No. 35272), the Discovery Grant (Project No. 3655), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canada Foundation for Innovation (Project No. 35272). This work was also financially supported by the Canada Research Chairs award to K.K. in “Bioelectrochemistry of Proteins” (Project No. 950-23116) and the MITACS Accelerate post-doctoral fellowship to A.R.

**Acknowledgments:** The authors would like to thank the Department of Physical and Environmental Sciences, University of Toronto Scarborough, and Lupos Biotechnology Inc. for their support.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Grotenhermen, F.; Russo, E. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential; Routledge: New York, NY, USA, 2013.
2. Farag, S.; Kaysr, O. The Cannabis Plant: Botanical Aspects. In Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment; Elsevier Inc.: Amsterdam, The Netherlands, 2017; pp. 3–12. ISBN 9780128008270.
3. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A.J. The therapeutic potential of cannabis. *Lancet Neurol.* 2003, 2, 291–298. [CrossRef]
4. Papagianni, E.P.; Stevenson, C.W. Cannabinoid Regulation of Fear and Anxiety: An Update. *Curr. Psychiatry Rep.* 2019, 21, 38. [CrossRef] [PubMed]
5. Brenneisen, R. *Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents*; Humana Press: Totowa, NJ, USA, 2007; pp. 17–49.
6. Bonini, S.A.; Premoli, M.; Tambaro, S.; Kumar, A.; Maccarinelli, G.; Memo, M.; Mastinu, A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. *J. Ethnopharmacol.* 2018, 227, 300–315. [CrossRef] [PubMed]
7. Mccalister, S.D.; Soroceanu, L.; Desprez, P.Y. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. *J. Neuroimmune Pharmacol.* 2015, 10, 255–267. [CrossRef] [PubMed]
8. McPartland, J.M.; Russo, E.B. Cannabis and Cannabis Extracts. *J. Cannabis Ther.* 2008, 1, 103–132. [CrossRef]
9. Pollastro, F.; Minassi, A.; Fresu, L.G. Cannabis Phenolics and their Bioactivities. *Curr. Med. Chem.* 2018, 25, 1160–1185. [CrossRef]
10. Prandi, C.; Blangetti, M.; Namdar, D.; Koltai, H. Structure-activity relationship of cannabis derived compounds for the treatment of neuronal activity-related diseases. *Molecules* 2018, 23, 1526. [CrossRef]
11. Eubanks, L.M.; Rogers, C.J.; Beuscher, A.E.; Koob, G.F.; Olson, A.J.; Dickerson, T.J.; Janda, K.D.; Janda, K.D. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. *Mol. Pharm.* 2006, 3, 773–777. [CrossRef]
12. Marsicano, G.; Moosmann, B.; Hermann, H.; Lutz, B.; Behl, C. Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. *J. Neurochem.* **2002**, *80*, 448–456. [CrossRef]

13. Niesink, R.J.M.; van Laar, M.W. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? *Front. Psychiatry* **2013**, *4*, 130. [CrossRef]

14. Kozela, E.; Juknat, A.; Kaushansky, N.; Rimmerman, N.; Ben-Nun, A.; Vogel, Z. Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype. *J. Neuroimmune Pharmacol.* **2013**, *8*, 1265–1276. [CrossRef] [PubMed]

15. Twitchell, W.; Brown, S.; Mackie, K. Cannabinoids Inhibit N- and P/Q-Type Calcium Channels in Cultured Rat Hippocampal Neurons. *J. Neurophysiol.* **1997**, *78*, 43–50. [CrossRef] [PubMed]

16. Hampson, A.J.; Grimaldi, M.; Lolic, M.; Wink, D.; Rosenthal, R.; Axelrod, J. Neuroprotective Antioxidants from Marijuana. *Ann. N. Y. Acad. Sci.* **2006**, *999*, 274–282. [CrossRef]

17. Hacke, A.C.M.; Lima, D.; De Costa, F.; Deshmukh, K.; Li, N.; Chow, A.M.; Marques, J.A.; Pereira, R.P.; Kerman, K. Probing the antioxidant activity of Δ9-tetrahydrocannabinol and cannabidiol in Cannabis sativa extracts. *Analyst* **2019**, *144*, 4952–4961. [CrossRef] [PubMed]

18. Stadtman, E.R.; Oliver, C.N. Metal-catalyzed oxidation of proteins. Physiological consequences. *J. Biol. Chem.* **1991**, *266*, 2005–2008. [PubMed]

19. Betteridge, D.J. What is oxidative stress? *Metabolism.* **2000**, *49*, 3–8. [CrossRef]

20. Mukhopadhyay, P.; Rajesh, M.; Horváth, B.; Bátkai, S.; Park, O.; Tanchian, G.; Gao, R.Y.; Patel, V.; Wink, D.A.; Liaudet, L.; et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic. Biol. Med.* **2011**, *50*, 1368–1381. [CrossRef]

21. Esposito, G.; De Filippis, D.; Carnuccio, R.; Izzo, A.A.; Iuvone, T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. *J. Mol. Med.* **2006**, *84*, 253–258. [CrossRef]

22. Watt, G.; Karl, T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. *Front. Pharmacol.* **2017**, *8*, 20. [CrossRef]

23. Arnold, J.C.; Boucher, A.A.; Karl, T. The yin and yang of cannabis-induced psychosis: The actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. *Curr. Pharm. Des.* **2012**, *18*, 5113–5130. [CrossRef]

24. Zuardi, A.W.; Hallak, J.E.C.; Crippa, J.A.S. Interaction between cannabidiol and Δ9-tetrahydrocannabinol (THC): Influence of administration interval and dose ratio between the cannabinoids. *Psychopharmacology* **2012**, *219*, 247–249. [CrossRef] [PubMed]

25. Croxford, J.L. Therapeutic Potential of Cannabinoids in CNS Disease. *CNS Drugs* **2003**, *17*, 179–202. [CrossRef] [PubMed]

26. Baker, D.; Pryce, G. The therapeutic potential of cannabis in multiple sclerosis. *Expert Opin. Investig. Drugs* **2003**, *12*, 561–567. [CrossRef]

27. Maroon, J.; Bost, J. Review of the neurological benefits of phytocannabinoids. *Surg. Neurol. Int.* **2018**, *9*, 91. [CrossRef] [PubMed]

28. Weier, M.; Hall, W. The Use of Cannabinoids in Treating Dementia. *Curr. Neurol. Neurosci. Rep.* **2017**, *17*, 1–9. [CrossRef] [PubMed]

29. Cristino, L.; Bisogno, T.; Di Marzo, V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. *Nat. Rev. Neurol.* **2020**, *16*, 9–29. [CrossRef]

30. Schubert, D.; Kepecsia, D.; Liang, Z.; Dargusch, R.; Goldberg, J.; Maher, P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. *Mol. Neurobiol.* **2019**, *56*, 7719–7730. [CrossRef]

31. Tarawneh, R.; Holtzman, D.M. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006148. [CrossRef]

32. Sebastián-Serrano, Á.; de Diego-García, L.; Diaz-Hernández, M. The Neurotoxic Role of Extracellular Tau Protein. *Int. J. Mol. Sci.* **2018**, *19*, 998. [CrossRef]

33. Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. *EMBO Mol. Med.* **2016**, *8*, 595–608. [CrossRef]

34. Tanzi, R.E.; Bertram, L. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective. *Cell* **2005**, *120*, 545–555. [CrossRef] [PubMed]
35. Butterfield, D.A.; Drake, J.; Pocernich, C.; Castegna, A. Evidence of oxidative damage in Alzheimer’s disease brain: Central role for amyloid beta-peptide. *Trends Mol. Med.* **2001**, *7*, 548–554. [CrossRef]

36. Lyras, L.; Cairns, N.J.; Jenner, A.; Jenner, P.; Halliwell, B. An Assessment of Oxidative Damage to Proteins, Lipids, and DNA in Brain from Patients with Alzheimer’s Disease. *J. Neurochem.* **2002**, *68*, 2061–2069. [CrossRef] [PubMed]

37. Tahmasebinia, F.; Emadi, S. Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron. *BioMetals* **2017**, *30*, 285–293. [CrossRef]

38. Rodriguez-Rodriguez, C.; Telpoukhovskaija, M.; Orvig, C. The art of building multifunctional metal-binding scaffolds from basic molecular building blocks for the potential application in neurodegenerative diseases. *Coord. Chem. Rev.* **2012**, *256*, 2308–2332. [CrossRef]

39. Dong, J.; Atwood, C.S.; Anderson, V.E.; Siedlak, S.L.; Smith, M.A.; Perry, G.; Carey, P.R. Metal binding and oxidation of amyloid-β within isolated senile plaque cores: Raman microscopic evidence. *Biochemistry* **2003**, *42*, 2768–2773. [CrossRef]

40. Bruce, A.J.; Boling, W.; Kindy, M.S.; Peschon, J.; Kraemer, P.J.; Carpenter, M.K.; Holtsberg, F.W.; Mattson, M.P. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. *Nat. Med.* **1996**, *2*, 788–794. [CrossRef]

41. Kim, G.H.; Kim, J.E.; Rhie, S.J.; Yoon, S. The Role of Oxidative Stress in Neurodegenerative Diseases. *Exp. Neurobiol.* **2015**, *24*, 325–340. [CrossRef]

42. Atwood, C.S.; Scarpa, R.C.; Huang, X.; Moir, R.D.; Jones, W.D.; Fairlie, D.P.; Tanzi, R.E.; Bush, A.I. Characterization of copper interactions with Alzheimer amyloid β peptides: Identification of an attomolar-affinity copper binding site on amyloid β1-42. *J. Neurochem.* **2000**, *75*, 1219–1233. [CrossRef]

43. Butterfield, D.A.; Swomley, A.M.; Sultana, R. Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. *Antioxid. Redox Signal.* **2013**, *19*, 823–835. [CrossRef]

44. Ahmadi, S.; Zhu, S.; Sharma, R.; Wu, B.; Soong, R.; Majumdar, R.D.; Wilson, D.J.; Simpson, A.J.; Kraatz, H.-B. Aggregation of Microtubule Binding Repeats of Tau Protein is Promoted by Cu2+. *ACS Omega* **2019**, *4*, 5356–5366. [CrossRef] [PubMed]

45. Ahmadi, S.; Zhu, S.; Sharma, R.; Wilson, D.J.; Kraatz, H.-B. Interaction of metal ions with tau protein. The case for a metal-mediated tau aggregation. *J. Inorg. Biochem.* **2019**, *194*, 44–51. [CrossRef] [PubMed]

46. Sarne, Y. THC for age-related cognitive decline? *Aging (Albany NY)* **2018**, *10*, 3628. [CrossRef] [PubMed]

47. Volicer, L.; Stelly, M.; Morris, J.; McLaughlin, J.; Volicer, B.J. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. *Int. J. Geriatr. Psychiatry* **1997**, *12*, 913–919. [CrossRef]

48. Cao, C.; Li, Y.; Liu, H.; Bai, G.; Mayl, J.; Lin, X.; Sutherland, K.; Nabar, N.; Cai, J. The potential therapeutic effects of THC on Alzheimer’s disease. *J. Alzheimers. Dis.* **2014**, *42*, 973–984. [CrossRef]

49. Janefford, E.; Máág, J.L.V.; Harvey, B.S.; Smid, S.D. Cannabinoid Effects on β Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro. *Cell. Mol. Neurobiol.* **2014**, *34*, 31–42. [CrossRef]

50. Wang, C.M.; Yang, C.Q.; Cheng, B.H.; Chen, J.; Bai, B. Orexin-A protects SH-SYSY cells against H2O2-induced oxidative damage via the PI3K/MEK1/2/ERK1/2 signaling pathway. *Int. J. Immunopathol. Pharmacol.* **2018**, *32*, 1–10. [CrossRef]

51. Chetsawang, B.; Putthaprasart, C.; Phansuwan-Pujito, P.; Govitrapong, P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SYSY cultured cells: Involvement of nuclear factor kappa B, Bax and Bcl-2. *J. Pineal Res.* **2006**, *41*, 116–123. [CrossRef]

52. Harvey, B.S.; Ohlsson, K.S.; Máág, J.L.V.; Musgrave, I.F.; Smid, S.D. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro. *Neurotoxicology* **2012**, *33*, 138–146. [CrossRef]

53. Acevedo, K.M.; Hung, Y.H.; Dalzieil, A.H.; Li, Q.X.; Laughton, K.; Wikhe, K.; Rembach, A.; Roberts, B.; Masters, C.L.; Bush, A.L.; et al. Copper promotes the trafficking of the amyloid precursor protein. *J. Biol. Chem.* **2011**, *286*, 8252–8262. [CrossRef]

54. Oguchi, T.; Ono, R.; Tsuiji, M.; Shozawa, H.; Somei, M.; Inagaki, M.; Mori, Y.; Yasumoto, T.; Ono, K.; Kiuchi, Y. Cilostazol suppresses Aβ-induced neurotoxicity in SH-SYSY cells through inhibition of oxidative stress and MAPK signaling pathway. *Front. Aging Neurosci.* **2017**, *9*, 337. [CrossRef] [PubMed]
55. Guesmi, F.; Bellamine, H.; Landoulsi, A. Hydrogen peroxide-induced oxidative stress, acetylcholinesterase inhibition, and mediated brain injury attenuated by *Thymus algeriensis*. *Appl. Physiol. Nutr. Metab*. 2018, 43, 1275–1281. [CrossRef]

56. Cheignon, C.; Jones, M.; Atrián-Blasco, E.; Kieffer, I.; Faller, P.; Collin, F.; Hureau, C. Identification of key structural features of the elusive Cu–Aβ complex that generates ROS in Alzheimer’s disease. *Chem. Sci.* 2017, 8, 5107–5118. [CrossRef] [PubMed]

57. Uttara, B.; Singh, A.V.; Zamboni, P.; Mahajan, R.T. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options. *Curr. Neuropharmacol.* 2009, 7, 65–74. [CrossRef]

58. Mathew, M.; Subramanian, S. In Vitro Screening for Anti-Cholinesterase and Antioxidant Activity of Methanolic Extracts of Ayurvedic Medicinal Plants Used for Cognitive Disorders. *PLoS ONE* 2014, 9, 86804. [CrossRef] [PubMed]

59. Dhanasekaran, S.; Perumal, P.; Palayan, M. In-vitro Screening for acetylcholinesterase enzyme inhibition potential and antioxidant activity of extracts of Ipomoea aquatica Forsk: Therapeutic lead for Alzheimer’s disease. *J. Appl. Pharm. Sci.* 2015, 5, 12–016. [CrossRef]

60. Ząbek-Adamska, A.; Drożdż, R.; Naskalski, J.W. Dynamics of reactive oxygen species generation in the presence of copper (II)–histidine complex and cysteine. *Acta Biochim. Pol.* 2013, 60, 565–571. [CrossRef]

61. Su, X.-Y.; Wu, W.-H.; Huang, Z.-P.; Hu, J.; Lei, P.; Yu, C.-H.; Zhao, Y.-F.; Li, Y.-M. Hydrogen peroxide can be generated by tau in the presence of Cu(II). *Biochem. Biophys. Res. Commun.* 2007, 358, 661–665. [CrossRef]

62. Kaur, A.; Narang, S.S.; Kaur, A.; Mann, S.; Priyadarshi, N.; Goyal, B.; Singhal, N.K.; Goyal, D. Multifunctional Mono-Triazole Derivatives Inhibit Aβ42 Aggregation and Cu2+-Mediated Aβ42 Aggregation and Protect against Aβ42-Induced Cytotoxicity. *Chem. Res. Toxicol.* 2019, 32, 1824–1839. [CrossRef]

63. Omar, S.H.; Scott, C.J.; Hamlin, A.S.; Obied, H.K. Olive biophenols reduces alzheimer’s pathology in SH-SY5Y cells and APPswe mice. *Int. J. Mol. Sci.* 2019, 20, 125. [CrossRef]

64. Murphy, M.P.; LeVine, H., III. Alzheimer’s disease and the amyloid-beta peptide. *J. Alzheimers. Dis.* 2010, 19, 311–323. [CrossRef]

65. Cheignon, C.; Tomas, M.; Faller, P.; Hureau, C.; Collin, F. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. *Relox Biol.* 2018, 14, 450–464. [CrossRef] [PubMed]

66. Faller, P.; Hureau, C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-β peptide. *Dalton. Trans.* 2009, 1080–1094. [CrossRef] [PubMed]

67. Lin, C.-J.; Huang, H.-C.; Jiang, Z.-F. Cu(II) interaction with amyloid-β peptide: A review of neuroactive mechanisms in AD brains. *Brain Res. Bull.* 2010, 82, 235–242. [CrossRef] [PubMed]

68. Squitti, R.; Barbati, G.; Rossi, L.; Ventriglia, M.; Dal Forno, G.; Cesaretti, S.; Moffa, F.; Caridi, I.; Cassetta, E.; Pasqualetti, P.; et al. Excess of noncereuloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau. *Neurology* 2006, 67, 76–82. [CrossRef] [PubMed]

69. Irakli, M.; Tsaliiki, E.; Kalivas, A.; Kleisiaris, F.; Sarrou, E.; Cook, C.M. Effect of genotype and growing year on the nutritional, phytochemical, and antioxidant properties of industrial hemp (*Cannabis sativa* L.) seeds. *Antioxidants* 2019, 8, 491. [CrossRef]

70. di Giacomo, V.; Chiavaroli, A.; Orlando, G.; Cataldi, A.; Rapino, M.; di Valerio, V.; Leone, S.; Brunetti, L.; Menghini, L.; Recinella, L.; et al. Neuroprotective and neuromodulatory effects induced by cannabidiol and cannabigerol in rat hypo-E22 cells and isolated hypothalamus. *Antioxidants* 2020, 9, 71. [CrossRef]

71. Presgraves, S.P.; Ahmed, T.; Borwege, S.; Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. *Neurotox. Res.* 2003, 5, 579–598. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.